These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34520436)

  • 21. Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells.
    Tanizaki J; Okamoto I; Takezawa K; Sakai K; Azuma K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Janne PA; Nakagawa K
    Br J Cancer; 2012 Feb; 106(4):763-7. PubMed ID: 22240786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
    Heuckmann JM; Balke-Want H; Malchers F; Peifer M; Sos ML; Koker M; Meder L; Lovly CM; Heukamp LC; Pao W; Küppers R; Thomas RK
    Clin Cancer Res; 2012 Sep; 18(17):4682-90. PubMed ID: 22912387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
    Shiihara J; Ohyanagi F; Amari H; Toda M; Tahara H; Yuzawa M; Maeda Y; Nomura M; Mizushina Y; Nagai Y; Ohta H; Yamaguchi Y
    Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer.
    Tanimura K; Yamada T; Horinaka M; Katayama Y; Fukui S; Morimoto K; Nakano T; Tokuda S; Morimoto Y; Iwasaku M; Kaneko Y; Uchino J; Yoneda K; Yano S; Sakai T; Takayama K
    Cancer Lett; 2021 Dec; 522():119-128. PubMed ID: 34534615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.
    Funazo T; Tsuji T; Ozasa H; Furugaki K; Yoshimura Y; Oguri T; Ajimizu H; Yasuda Y; Nomizo T; Sakamori Y; Yoshida H; Kim YH; Hirai T
    Mol Cancer Ther; 2020 Jun; 19(6):1320-1327. PubMed ID: 32217741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lysophosphatidic Acid Stimulates Mitogenic Activity and Signaling in Human Neuroblastoma Cells through a Crosstalk with Anaplastic Lymphoma Kinase.
    Dedoni S; Olianas MC; Onali P
    Biomolecules; 2024 May; 14(6):. PubMed ID: 38927035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via
    Chuang TP; Lai WY; Gabre JL; Lind DE; Umapathy G; Bokhari AA; Bergman B; Kristenson L; Thorén FB; Le A; Doebele RC; Van den Eynden J; Palmer RH; Hallberg B
    Proc Natl Acad Sci U S A; 2023 Feb; 120(8):e2216479120. PubMed ID: 36791109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
    Chen H; Lin C; Peng T; Hu C; Lu C; Li L; Wang Y; Han R; Feng M; Sun F; He Y
    Cell Death Dis; 2020 Feb; 11(2):111. PubMed ID: 32041944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.
    Tsuji T; Ozasa H; Aoki W; Aburaya S; Funazo T; Furugaki K; Yoshimura Y; Ajimizu H; Okutani R; Yasuda Y; Nomizo T; Uemasu K; Hasegawa K; Yoshida H; Yagi Y; Nagai H; Sakamori Y; Ueda M; Hirai T; Kim YH
    Mol Cancer Res; 2019 Jan; 17(1):212-224. PubMed ID: 30171175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
    Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K
    Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
    Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report.
    Sun K; Nie L; Nong L; Cheng Y
    Thorac Cancer; 2021 Jun; 12(12):1927-1930. PubMed ID: 33960639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
    BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
    Zhang SS; Nagasaka M; Zhu VW; Ou SI
    Lung Cancer; 2021 Aug; 158():126-136. PubMed ID: 34175504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.
    Tanimoto A; Yamada T; Nanjo S; Takeuchi S; Ebi H; Kita K; Matsumoto K; Yano S
    Oncotarget; 2014 Jul; 5(13):4920-8. PubMed ID: 24952482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion.
    Lin X; Yang X; Tan Y; Duan Q; He M
    Invest New Drugs; 2022 Oct; 40(5):1160-1163. PubMed ID: 35608716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
    Hui B; Zhang J; Shi X; Xing F; Shao YW; Wang Y; Zhang X; Wang S
    Jpn J Clin Oncol; 2020 Dec; 50(12):1470-1474. PubMed ID: 32845005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
    Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
    Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
    Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.